Psoriasis – Emerging Therapies – Tremfya Launch Tracking Wave 2 (US)
In the past decade, TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen), as well as IL-12/23 inhibitor Stelara (Janssen), have been leading the U.S. psoriasis biologics market. However, the recent wave of U.S. approvals for novel psoriasis agents—Celgene’s Otezla (2014), Novartis’s Cosentyx (2015), Eli Lilly’s Taltz (2016), Valeant’s Siliq (2017), Janssen’s Tremfya (2017), and Sun Pharma’s Ilumya (2018)—is anticipated to substantially alter the market landscape. The Psoriasis Emerging Therapies series includes three waves that will track the awareness, trial, and use of Tremfya after its launch in July 2017 for the treatment of psoriasis. In addition, the series will examine physicians’ anticipation of future trends in psoriasis treatment, particularly Tremfya’s uptake, and assess Janssen’s promotional efforts.
Questions Answered:
- What is the awareness of, familiarity with, and perceptions related to Tremfya among U.S. dermatologists?
- According to prescribers, to which patients are they prescribing Tremfya, why are they prescribing Tremfya, and how satisfied are they with Tremfya ?
- How do prescribers and nonprescribers compare across key metrics?
- How is the trial and adoption of Tremfya tracking compared to other recent product launches in the autoimmune market?
Product Description:
Emerging Therapies is a three-wave series based on primary research data collected at 1, 6, and 12 months post-commercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and use of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.
Table of contents
- Psoriasis - Emerging Therapies - Tremfya Launch Tracking Wave 2 (US)
- Key Findings
- Benchmarking Tremfya's Launch Success vs. Other Launched Drugs
- Prescriber and Nonprescriber Profiles
- Differences Between Tremfya Prescribers and Nonprescribers
- Differences Between Tremfya Prescriber and Nonprescriber Profiles
- Tremfya Awareness and Perceptions
- Unaided and Aided Awareness of Tremfya
- Unaided Awareness of Approved Drugs for Psoriasis
- Recent Changes Made to Psoriasis Treatment
- Awareness of Tremfya
- Awareness of Tremfya's Approval for Psoriasis
- Awareness of Tremfya's Dosing
- Estimated Cost of Tremfya
- Familiarity with Tremfya
- Sources of Familiarity with Tremfya
- Initial Reaction to and Interest in Tremfya
- Tremfya Product Profile
- Initial Reaction to Tremfya After Viewing Product Profile
- Initial Reaction to Tremfya After Viewing Product Profile: Mean
- Initial Reaction to Key Attributes of Tremfya After Viewing Product Profile
- Initial Reaction to Key Attributes of Tremfya After Viewing Product Profile: Mean
- Interest in Learning More About Tremfya
- Interest in Learning More About Tremfya: Mean
- Impressions of Tremfya
- Tremfya Attributes of Which Dermatologists Were Unaware
- Aspects of Tremfya Profile of Which Dermatologists Were Unaware
- Perceived Uniqueness of Tremfya
- Perceived Uniqueness of Tremfya: Mean
- Risk-Benefit Ratio of Tremfya
- Risk-Benefit Ratio of Tremfya: Mean
- Unaided Advantages of Tremfya
- Unaided Disadvantages of Tremfya
- Prescriber and Nonprescriber Profiles
- Differences Between Tremfya Prescriber and Nonprescriber Profiles
- Unaided and Aided Awareness of Tremfya
- Tremfya Trial and Use
- Willingness to Prescribe Tremfya
- Willingness to Prescribe Tremfya to Psoriasis Patients
- Willingness to Prescribe Tremfya to Psoriasis Patients: Mean
- Impact of Attributes on Willingness to Prescribe Tremfya
- Impact of Attributes on Willingness to Prescribe Tremfya: Mean
- Number of Patients Currently Receiving Tremfya
- Tremfya Patient Volume
- Timing of Tremfya Prescription
- Tremfya Discontinuation Rate
- Agents to Which Patients Switched After Discontinuing Tremfya
- Biologics and Novel Oral Agents Currently Prescribed to Psoriasis Patients
- Disease Severity of Tremfya-Treated Patients
- Origination of Patients Treated with Tremfya
- Agents from Which Patients Were Switched to Tremfya
- Therapies to Which Tremfya Was Added
- Reasons for Prescribing Tremfya
- Number of Patient Inquiries for Tremfya
- Number of Patient Inquiries for Tremfya: Mean Number of Patients
- Result of Specific Patient Requests for Tremfya
- Reasons for Not Yet Prescribing Tremfya
- Anticipated Tremfya Use
- Nonprescriber Timeline for Tremfya Trial
- Anticipated New Tremfya Users in the Next Month
- Candidates for Tremfya by Psoriasis Patient Population
- Candidates for Tremfya by Treatment History
- Therapies That Tremfya Is Likely to Replace
- Obstacles to Prescribing Tremfya
- Anticipated Prescribing of Biologics and Novel Oral Agents for Psoriasis in the Next Six Months
- Tremfya Performance on Key Attributes
- Overall Satisfaction with Tremfya
- Reasons for High Overall Satisfaction with Tremfya
- Ease of Tremfya's Managed Care Approval Process
- Requirements for Tremfya's Managed Care Approval
- Mean Total Tremfya Performance on Key Attributes
- Mean Tremfya Performance on Key Attributes: Prescribers vs. Nonprescribers
- Tremfya Performance on Key Attributes: Prescribers vs. Nonprescribers
- Total Tremfya Performance on Key Attributes
- Willingness to Prescribe Tremfya
- Effectiveness of Face-to-Face Detailing for Tremfya
- Tremfya Sales Representative Frequency and Reach
- Most Recent Contact with a Tremfya Representative
- Frequency of Tremfya Representative Visits to Surveyed Dermatologists
- Frequency of Tremfya Representative Visits to Surveyed Dermatologists: Mean
- Satisfaction with Tremfya Sales Representative
- Performance of Tremfya Sales Representatives
- Performance of Tremfya Sales Representatives: Mean
- Tremfya Message Recall
- Message Recall During Recent Detail
- Percentage of Physicians Who Received Ideal Tremfya Candidate Suggestion from Representative
- Ideal Tremfya Candidate Suggestions Made by Representative
- Materials Used During Tremfya Sales Representative Visit
- Agents Positioned Against Tremfya During Representative Visit
- Tremfya Sales Representative Frequency and Reach
- Appendix
- Additional Primary Market Research
- Anticipated New Tremfya Users in the Next Month: Mean Number of Patients
- Patients Treated by Disease Severity
- Percentage of Patients Receiving Prescription Drug Therapy
- Percentage of Patients Receiving Prescription Drug Therapy by Treatment Category
- Percentage of Patients Receiving Phototherapy
- Timing of Tremfya Prescription: Mean Number of Patients
- Tremfya Discontinuation Rate: Mean Number of Patients
- Disease Severity of Tremfya-Treated Patients: Mean Number of Patients
- Reasons for Discontinuing Tremfya
- Average Time Between Tremfya Initiation and Discontinuation
- Average Time Between Tremfya Initiation and Discontinuation: Mean Number of Patients
- Abbreviations
- Additional Primary Market Research
- Key Findings
Mohit Nasa, M.B.A., is a principal analyst on the Immune and Inflammatory Disorders team at Clarivate. He has authored content on such indications as systemic lupus erythropoiesis, psoriasis, asthma, and rheumatoid arthritis. Previously, he worked as a senior business analyst at Novartis, where he was responsible for end-to-end market assessment and related projects for Novartis’s asthma brand Xolair. Mr. Nasa holds a bachelor’s degree in pharmacy and an M.B.A. in marketing and CRM from Amity Business School in India.